PPARG epigenetic deregulation and its role in colorectal tumorigenesis

PPAR Research

Volumn , Issue , 2012, Pages

  Sabatino, Lina ^a   Fucci, Alessandra ^a   Pancione, Massimo ^a   Colantuoni, Vittorio ^a  

^a UNIVERSITY OF SANNIO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRILYSIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTAGLANDIN E2; TRASTUZUMAB; UNTRANSLATED RNA;

CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CELL CYCLE ARREST; COLORECTAL CANCER; DOWN REGULATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; METHYLATION; NONHUMAN; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

EID: 84864929802     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2012/687492     Document Type: Review

References (143)

1. Michalik L., Desvergne B., Wahli W., Peroxisome-proliferator-activated receptors and cancers: complex stories Nature Reviews Cancer 2004 4 1 61 70 (Pubitemid 38082154)
2. Schweitzer A., Knauer S. K., Stauber R. H., Nuclear receptors in head and neck cancer: current knowledge and perspectives International Journal of Cancer 2010 126 4 801 809
3. Lehrke M., Lazar M. A., The many faces of PPAR Cell 2005 123 6 993 999
4. Issemann I., Green S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 1990 347 6294 645 650
5. Kliewer S. A., Forman B. M., Blumberg B., Ong E. S., Borgmeyer U., Mangelsdorf D. J., Umesono K., Evans R. M., Differential expression and activation of a family of murine peroxisome proliferator-activated receptors Proceedings of the National Academy of Sciences of the United States of America 1994 91 15 7355 7359 (Pubitemid 24226862)
6. Mangelsdorf D. J., Evans R. M., The RXR heterodimers and orphan receptors Cell 1995 83 6 841 850 (Pubitemid 26006526)
7. Pyper S. R., Viswakarma N., Yu S., Reddy J. K., PPAR : energy combustion, hypolipidemia, inflammation and cancer Nuclear Receptor Signaling 2010 8 e002
8. Wang D., DuBois R. N., Peroxisome proliferator-activated receptors and progression of colorectal cancer PPAR Research 2008 2008 7
9. Scatena R., Bottoni P., Giardina B., Mitochondria, PPARs, and cancer: is receptor-independent action of PPAR agonists a key? PPAR Research 2008 2008 10
10. Desvergne B., Wahli W., Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocrine Reviews 1999 20 5 649 688 (Pubitemid 30650602)
11. Kersten S., Desvergne B., Wahli W., Roles of PPARS in health and disease Nature 2000 405 6785 421 424 (Pubitemid 30367411)
12. Lee C. H., Olson P., Evans R. M., Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors Endocrinology 2003 144 6 2201 2207 (Pubitemid 36629867)
13. Evans R. M., Barish G. D., Wang Y. X., PPARs and the complex journey to obesity Nature Medicine 2004 10 4 355 361 (Pubitemid 38508511)
14. Nahlé Z., PPAR trilogy from metabolism to cancer Current Opinion in Clinical Nutrition and Metabolic Care 2004 7 4 397 402 (Pubitemid 40340645)
15. Michalik L., Auwerx J., Berger J. P., Chatterjee V. K., Glass C. K., Gonzalez F. J., Grimaldi P. A., Kadowaki T., Lazar M. A., O'Rahilly S., Palmer C. N. A., Plutzky J., Reddy J. K., Spiegelman B. M., Staels B., Wahli W., International union of pharmacology. LXI. Peroxisome proliferator-activated receptors Pharmacological Reviews 2006 58 4 726 741 (Pubitemid 44833742)
16. Michalik L., Wahli W., Involvement of PPAR nuclear receptors in tissue injury and wound repair Journal of Clinical Investigation 2006 116 3 598 606 (Pubitemid 43326864)
17. Grabacka M., Placha W., Plonka P. M., Pajak S., Urbanska K., Laidler P., Slominski A., Inhibition of melanoma metastases by fenofibrate Archives of Dermatological Research 2004 296 2 54 58 (Pubitemid 39024837)
18. Grabacka M., Plonka P. M., Urbanska K., Reiss K., Peroxisome proliferator-Activated receptor activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt Clinical Cancer Research 2006 12 10 3028 3036 (Pubitemid 43837347)
19. Strakova N., Ehrmann J., Bartos J., Malikova J., Dolezel J., Kolar Z., Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors Neoplasma 2005 52 2 126 136
20. Grau R., Punzn C., Fresno M., Iiguez M. A., Peroxisome-proliferator- activated receptor agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1 Biochemical Journal 2006 395 1 81 88
21. Harman F. S., Nicol C. J., Marin H. E., Ward J. M., Gonzalez F. J., Peters J. M., Peroxisome proliferator-activated receptor- attenuates colon carcinogenesis Nature Medicine 2004 10 5 481 483 (Pubitemid 38667905)
22. Reed K. R., Sansom O. J., Hayes A. J., Gescher A. J., Winton D. J., Peters J. M., Clarke A. R., PPAR status and Apc-mediated tumourigenesis in the mouse intestine Oncogene 2004 23 55 8992 8996 (Pubitemid 39657790)
23. Stephen R. L., Gustafsson M. C. U., Jarvis M., Tatoud R., Marshall B. R., Knight D., Ehrenborg E., Harris A. L., Wolf C. R., Palmer C. N. A., Activation of peroxisome proliferator-activated receptor stimulates the proliferation of human breast and prostate cancer cell lines Cancer Research 2004 64 9 3162 3170 (Pubitemid 38581418)
24. Glinghammar B., Skogsberg J., Hamsten A., Ehrenborg E., PPAR activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells Biochemical and Biophysical Research Communications 2003 308 2 361 368 (Pubitemid 36937188)
25. Fajas L., Fruchart J. C., Auwerx J., PPAR 3 mRNA: a distinct PPAR mRNA subtype transcribed from an independent promoter FEBS Letters 1998 438 1-2 55 60 (Pubitemid 28517834)
26. Al-Shali K., Cao H., Knoers N., Hermus A. R., Tack C. J., Hegele R. A., A single-base mutation in the peroxisome proliferator-activated receptor 4 promoter associated with altered in vitro expression and partial lipodystrophy Journal of Clinical Endocrinology and Metabolism 2004 89 11 5655 5660 (Pubitemid 39518455)
27. Zhu Y., Alvares K., Huang Q., Rao M. S., Reddy J. K., Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver Journal of Biological Chemistry 1993 268 36 26817 26820 (Pubitemid 24006385)
28. Meirhaeghe A., Amouyel P., Impact of genetic variation of PPAR in humans Molecular Genetics and Metabolism 2004 83 1-2 93 102 (Pubitemid 39311284)
29. Tontonoz P., Hu E., Graves R. A., Budavari A. I., Spiegelman B. M., mPPAR 2: tissue-specific regulator of an adipocyte enhancer Genes and Development 1994 8 10 1224 1234
30. Hummasti S., Tontonoz P., The peroxisome proliferator-activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis Molecular Endocrinology 2006 20 6 1261 1275 (Pubitemid 43804815)
31. Yamashita D., Yamaguchi T., Shimizu M., Nakata N., Hirose F., Osumi T., The transactivating function of peroxisome proliferator-activated receptor is negatively regulated by SUMO conjugation in the amino-terminal domain Genes to Cells 2004 9 11 1017 1029 (Pubitemid 39467975)
32. Renaud J. P., Moras D., Structural studies on nuclear receptors Cellular and Molecular Life Sciences 2000 57 12 1748 1769
33. Yessoufou A., Wahli W., Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels Swiss Medical Weekly 2010 140 13071
34. Mukherjee R., Jow L., Croston G. E., Paterniti J. R. Jr, Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPAR 2 versus PPAR 1 and activation with retinoid X receptor agonists and antagonists Journal of Biological Chemistry 1997 272 12 8071 8076 (Pubitemid 27137374)
35. Wang P., Renes J., Bouwman F., Bunschoten A., Mariman E., Keijer J., Absence of an adipogenic effect of rosiglitazone on mature 3T3-L1 adipocytes: increase of lipid catabolism and reduction of adipokine expression Diabetologia 2007 50 3 654 665 (Pubitemid 46215510)
36. Fajas L., Auboeuf D., Raspé E., Schoonjans K., Lefebvre A. M., Saladin R., Najib J., Laville M., Fruchart J. C., Deeb S., Vidal-Puig A., Flier J., Briggs M. R., Staels B., Vidal H., Auwerx J., The organization, promoter analysis, and expression of the human PPAR gene Journal of Biological Chemistry 1997 272 30 18779 18789 (Pubitemid 27318225)
37. Thompson E. A., PPAR physiology and pathology in gastrointestinal epithelial cells Molecules and Cells 2007 24 2 167 176 (Pubitemid 350177175)
38. Drori S., Girnun G. D., Tou L., Szwaya J. D., Mueller E., Kia X., Shivdasani R. A., Spiegelman B. M., Hic-5 regulates an epithelial program mediated by PPAR Genes and Development 2005 19 3 362 375 (Pubitemid 40189299)
39. Mann J., Chu D. C. K., Maxwell A., Oakley F., Zhu N. L., Tsukamoto H., Mann D. A., MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis Gastroenterology 2010 138 2 705 e4
40. Welch J. S., Ricote M., Akiyama T. E., Gonzalez F. J., Glass C. K., PPAR and PPAR negatively regulate specific subsets of lipopolysaccharide and IFN- target genes in macrophages Proceedings of the National Academy of Sciences of the United States of America 2003 100 11 6712 6717 (Pubitemid 36666645)
41. Ricote M., Glass C. K., PPARs and molecular mechanisms of transrepression Biochimica et Biophysica Acta 2007 1771 8 926 935 (Pubitemid 47198544)
42. Li M., Pascual G., Glass C. K., Peroxisome proliferator-activated receptor -dependent repression of the inducible nitric oxide synthase gene Molecular and Cellular Biology 2000 20 13 4699 4707 (Pubitemid 30396117)
43. Su C. G., Wen X., Bailey S. T., Jiang W., Rangwala S. M., Keilbaugh S. A., Flanigan A., Murthy S., Lazar M. A., Wu G. D., A novel therapy for colitis utilizing PPAR- ligands to inhibit the epithelial inflammatory response Journal of Clinical Investigation 1999 104 4 383 389 (Pubitemid 29534322)
44. Pascual G., Fong A. L., Ogawa S., Gamliel A., Li A. C., Perissi V., Rose D. W., Willson T. M., Rosenfeld M. G., Glass C. K., A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR- Nature 2005 437 7059 759 763 (Pubitemid 41486547)
45. Matsuyama M., Yoshimura R., A novel approach to anticancer therapies: peroxisome proliferator activator-receptor- as a new target therapy in the treatment of human urological cancer Endocrine, Metabolic and Immune Disorders 2009 9 1 76 83
46. Komar C. M., Peroxisome proliferator-activated receptors (PPARs) and ovarian function-implications for regulating steroidogenesis, differentiation, and tissue remodeling Reproductive Biology and Endocrinology 2005 3 41
47. Burstein H. J., Demetri G. D., Mueller E., Sarraf P., Spiegelman B. M., Winer E. P., Use of the peroxisome proliferator-activated receptor (PPAR) ligand troglitazone as treatment for refractory breast cancer: a phase II study Breast Cancer Research and Treatment 2003 79 3 391 397 (Pubitemid 36750946)
48. Copland J. A., Marlow L. A., Kurakata S., Fujiwara K., Wong A. K. C., Kreinest P. A., Williams S. F., Haugen B. R., Klopper J. P., Smallridge R. C., Novel high-affinity PPAR agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1 Oncogene 2006 25 16 2304 2317
49. Demetri G. D., Fletcher C. D. M., Mueller E., Sarraf P., Naujoks R., Campbell N., Spiegelman B. M., Singer S., Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor- ligand troglitazone in patients with liposarcoma Proceedings of the National Academy of Sciences of the United States of America 1999 96 7 3951 3956 (Pubitemid 29169017)
50. Mueller E., Sarraf P., Tontonoz P., Evans R. M., Martin K. J., Zhang M., Fletcher C., Singer S., Spiegelman B. M., Terminal differentiation of human breast cancer through PPAR Molecular Cell 1998 1 3 465 470 (Pubitemid 128378895)
51. Mehta R. G., Williamson E., Patel M. K., Koeffler H. P., A ligand of peroxisome proliferator-activated receptor, retinoids, and prevention of preneoplastic mammary lesions Journal of the National Cancer Institute 2000 92 5 418 423 (Pubitemid 30154824)
52. Cellai I., Petrangolini G., Tortoreto M., Pratesi G., Luciani P., Deledda C., Benvenuti S., Ricordati C., Gelmini S., Ceni E., Galli A., Balzi M., Faraoni P., Serio M., Peri A., In vivo effects of rosiglitazone in a human neuroblastoma xenograft British Journal of Cancer 2010 102 4 685 692
53. Heaney A. P., Fernando M., Melmed S., PPAR- receptor ligands: novel therapy for pituitary adenomas Journal of Clinical Investigation 2003 111 9 1381 1388 (Pubitemid 36554709)
54. Ohta K., Endo T., Haraguchi K., Hershman J. M., Onaya T., Ligands for peroxisome proliferator-activated receptor inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells Journal of Clinical Endocrinology and Metabolism 2001 86 5 2170 2177 (Pubitemid 32472935)
55. Kubota T., Koshizuka K., Williamson E. A., Asou H., Said J. W., Holden S., Miyoshi I., Koeffler H. P., Ligand for peroxisome proliferator-activated receptor (Troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo Cancer Research 1998 58 15 3344 3352 (Pubitemid 28371075)
56. Yin F., Wakino S., Liu Z., Kim S., Hsueh W. A., Collins A. R., Van Herle A. J., Law R. E., Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators Biochemical and Biophysical Research Communications 2001 286 5 916 922 (Pubitemid 32924859)
57. Kato M., Kusumi T., Tsuchida S., Tanaka M., Sasaki M., Kudo H., Induction of differentiation and peroxisome proliferator-activated receptor expression in colon cancer cell lines by troglitazone Journal of Cancer Research and Clinical Oncology 2004 130 2 73 79 (Pubitemid 38316669)
58. Tsubouchi Y., Sano H., Kawahito Y., Mukai S., Yamada R., Kohno M., Inoue K. I., Hla T., Kondo M., Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor- agonists through induction of apoptosis Biochemical and Biophysical Research Communications 2000 270 2 400 405 (Pubitemid 30446848)
59. Koga H., Sakisaka S., Harada M., Takagi T., Hanada S., Taniguchi E., Kawaguchi T., Sasatomi K., Kimura R., Hashimoto O., Ueno T., Yano H., Kojiro M., Sata M., Involvement of p21WAF1/Cip1, p27Kip1, and p18INK4c in troglitazone-induced cell-cycle arrest in human hepatoma cell lines Hepatology 2001 33 5 1087 1097 (Pubitemid 32378207)
60. Motomura W., Okumura T., Takahashi N., Obara T., Kohgo Y., Activation of peroxisome proliferator-activated receptor by troglitazone inhibits cell growth through the increase of p27(Kip1) in human pancreatic carcinoma cells Cancer Research 2000 60 19 5558 5564
61. Farrow B., Evers B. M., Activation of PPAR increases PTEN expression in pancreatic cancer cells Biochemical and Biophysical Research Communications 2003 301 1 50 53 (Pubitemid 36268846)
62. Lee S. Y., Hur G. Y., Jung K. H., Jung H. C., Lee S. Y., Kim J. H., Shin C., Shim J. J., In K. H., Kang K. H., Yoo S. H., PPAR- agonist increase gefitinib's antitumor activity through PTEN expression Lung Cancer 2006 51 3 297 301 (Pubitemid 43265812)
63. Zhang W., Wu N., Li Z., Wang L., Jin J., Zha X. L., PPAR activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404 Cancer Biology and Therapy 2006 5 8 1008 1014
64. Tachibana K., Yamasaki D., Ishimoto K., Doi T., The role of PPARs in cancer PPAR Research 2008 2008
65. Inoue H., Tanabe T., Umesono K., Feedback control of cyclooxygenase-2 expression through PPAR Journal of Biological Chemistry 2000 275 36 28028 28032
66. Liu H., Zang C., Fenner M. H., Possinger K., Elstner E., PPAR ligands and ATRA inhibit the invasion of human breast cancer cells in vitro Breast Cancer Research and Treatment 2003 79 1 63 74 (Pubitemid 36561044)
67. Shen D., Deng C., Zhang M., Peroxisome proliferator-activated receptor agonists inhibit the proliferation and invasion of human colon cancer cells Postgraduate Medical Journal 2007 83 980 414 419 (Pubitemid 46960828)
68. Gupta R. A., Sarraf P., Brockman J. A., Shappell S. B., Raftery L. A., Willson T. M., DuBois R. N., Peroxisome proliferator-activated receptor and transforming growth factor- pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22 Journal of Biological Chemistry 2003 278 9 7431 7438 (Pubitemid 36800748)
69. Satoh T., Toyoda M., Hoshino H., Monden T., Yamada M., Shimizu H., Miyamoto K., Mori M., Activation of peroxisome proliferator-activated receptor- stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells Oncogene 2002 21 14 2171 2180 (Pubitemid 34311371)
70. Chen G. G., Lee J. F. Y., Wang S. H., Chan U. P. F., Ip P. C., Lau W. Y., Apoptosis induced by activation of peroxisome-proliferator activated receptor- is associated with Bcl-2 and Nf-kB in human colon cancer Life Sciences 2002 70 22 2631 2646 (Pubitemid 34310556)
71. Xin X., Yang S., Kowalski J., Gerritsen M. E., Peroxisome proliferator-activated receptor ligands are potent inhibitors of angiogenesis in vitro and in vivo Journal of Biological Chemistry 1999 274 13 9116 9121 (Pubitemid 29164719)
72. Panigrahy D., Singer S., Shen L. Q., Butterfield C. E., Freedman D. A., Chen E. J., Moses M. A., Kilroy S., Duensing S., Fletcher C., Fletcher J. A., Hlatky L., Hahnfeldt P., Folkman J., Kaipainen A., PPAR ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis Journal of Clinical Investigation 2002 110 7 923 932
73. Kojima M., Morisaki T., Sasaki N., Nakano K., Mibu R., Tanaka M., Katano M., Increased nuclear factor- B activation in human colorectal carcinoma and its correlation with tumor progression Anticancer Research B 2004 24 2 675 681 (Pubitemid 38625006)
74. Zeng C., Xiao J. H., Chang M. J., Wang J. L., Beneficial effects of THSG on acetic acid-induced experimental colitis: involvement of upregulation of PPAR and inhibition of the Nf- B inflammatory pathway Molecules 2011 16 10 8552 8568
75. Pelletier L., Rebouissou S., Vignjevic D., Bioulac-Sage P., Zucman-Rossi J., HNF1 inhibition triggers epithelial-mesenchymal transition in human liver cancer cell lines BMC Cancer 2011 11 427
76. Reka A. K., Kurapati H., Narala V. R., Bommer G., Chen J., Standiford T. J., Keshamouni V. G., Peroxisome proliferator-activated receptor-g activation inhibits tumor metastasis by antagonizing smad3-mediated epithelial-mesenchymal transition Molecular Cancer Therapeutics 2010 9 12 3221 3232
77. Kristiansen G., Jacob J., Buckendahl A. C., Grtzmann R., Alldinger I., Sipos B., Klppel G., Bahra M., Langrehr J. M., Neuhaus P., Dietel M., Pilarsky C., Peroxisome proliferator-activated receptor is highly expressed in pancreatic cancer and is associated with shorter overall survival times Clinical Cancer Research 2006 12 21 6444 6451 (Pubitemid 44799717)
78. Tyagi S., Gupta P., Saini A., Kaushal C., Sharma S., The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases Journal of Advanced Pharmaceutical Technology and Research 2011 2 4 236 240
79. Ye F., Lemieux H., Hoppel C. L., Hanson R. W., Hakimi P., Croniger C. M., Puchowicz M., Anderson V. E., Fujioka H., Stavnezer E., Peroxisome proliferator-activated receptor (PPAR ) mediates a Ski oncogene-induced shift from glycolysis to oxidative energy metabolism Journal of Biological Chemistry 2011 286 46 40013 40024
80. Menendez J. A., Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives Biochimica et Biophysica Acta 2010 1801 3 381 391
81. Lee J., Drakaki A., Iliopoulos D., Struhl K., MiR-27b targets PPAR to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene. In press
82. Su W., Bush C. R., Necela B. M., Calcagno S. R., Murray N. R., Fields A. P., Thompson E. A., Differential expression, distribution, and function of PPAR- in the proximal and distal colon Physiological Genomics 2007 30 3 342 353 (Pubitemid 47296193)
83. Weitz J., Koch M., Debus J., Hhler T., Galle P. R., Bchler M. W., Colorectal cancer Lancet 2005 365 9454 153 165 (Pubitemid 40091806)
84. Saez E., Tontonoz P., Nelson M. C., Alvarez J. G. A., Ming U T., Baird S. M., Thomazy V. A., Evans R. M., Activators of the nuclear receptor PPAR enhance colon polyp formation Nature Medicine 1998 4 9 1058 1061 (Pubitemid 28417339)
85. Lefebvre M., Paulweber B., Fajas L., Activation of the peroxisome proliferator-activated receptor promotes the development of colon tumors in C57BL/6J-APCMin/+ mice Nature Medicine 1998 4 9 1053 1057
86. Niho N., Takahashi M., Kitamura T., Shoji Y., Itoh M., Noda T., Sugimura T., Wakabayashi K., Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands Cancer Research 2003 63 18 6090 6095 (Pubitemid 37187515)
87. Niho N., Takahashi M., Shoji Y., Takeuchi Y., Matsubara S., Sugimura T., Wakabayashi K., Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR ligand Cancer Science 2003 94 11 960 964 (Pubitemid 37508978)
88. McAlpine C. A., Barak Y., Matise I., Cormier R. T., Intestinal-specific PPAR deficiency enhances tumorigenesis in ApcMin/+ mice International Journal of Cancer 2006 119 10 2339 2346 (Pubitemid 44546953)
89. Bush C. R., Havens J. M., Necela B. M., Su W., Chen L., Yanagisawa M., Anastasiadis P. Z., Guerra R., Luxon B. A., Thompson E. A., Functional genomic analysis reveals cross-talk between peroxisome proliferator-activated receptor and calcium signaling in human colorectal cancer cells Journal of Biological Chemistry 2007 282 32 23387 23401 (Pubitemid 47311964)
90. Gupta R. A., Sarraf P., Mueller E., Brockman J. A., Prusakiewicz J. J., Eng C., Willson T. M., DuBois R. N., Peroxisome proliferator-activated receptor -mediated differentiation: a mutation in colon cancer cells reveals divergent and cell type-specific mechanisms Journal of Biological Chemistry 2003 278 25 22669 22677 (Pubitemid 36830326)
91. Yoshizumi T., Ohta T., Ninomiya I., Terada I., Fushida S., Fujimura T., Nishimura G. I., Shimizu K., Yi S., Miwa K., Thiazolidinedione, a peroxisome proliferator-activated receptor- ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects International journal of oncology 2004 25 3 631 639
92. Kohno H., Yoshitani S., Takashima S., Okumura A., Hosokawa M., Yamaguchi N., Tanaka T., Troglitazone, a ligand for peroxisome proliferator-activated receptor, inhibits chemically-induced aberrant crypt foci in rats Japanese Journal of Cancer Research 2001 92 4 396 403 (Pubitemid 32427775)
93. Tanaka T., Kohno H., Yoshitani S. I., Takashima S., Okumura A., Murakami A., Hosokawa M., Ligands for peroxisome proliferator-activated receptors and inhibit chemically induced colitis and formation of aberrant crypt foci in rats Cancer Research 2001 61 6 2424 2428 (Pubitemid 32685818)
94. Osawa E., Nakajima A., Wada K., Ishimine S., Fujisawa N., Kawamori T., Matsuhashi N., Kadowaki T., Ochiai M., Sekihara H., Nakagama H., Peroxisome proliferator-activated receptor ligands suppress colon carcinogenesis induced by azoxymethane in mice Gastroenterology 2003 124 2 361 367 (Pubitemid 36169253)
95. Palakurthi S. S., Aktas H., Grubissich L. M., Mortensen R. M., Halperin J. A., Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor and mediated by inhibition of translation initiation Cancer Research 2001 61 16 6213 6218 (Pubitemid 32762559)
96. Peraza M. A., Burdick A. D., Marin H. E., Gonzalez F. J., Peters J. M., The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR) Toxicological Sciences 2006 90 2 269 295
97. Girnun G. D., Smith W. M., Drori S., Sarraf P., Mueller E., Eng C., Nambiar P., Rosenberg D. W., Bronson R. T., Edelmann W., Kucherlapati R., Gonzalez F. J., Spiegelman B. M., APC-dependent suppression of colon carcinogenesis by PPAR Proceedings of the National Academy of Sciences of the United States of America 2002 99 21 13771 13776 (Pubitemid 35215456)
98. Balkwill F., Charles K. A., Mantovani A., Smoldering and polarized inflammation in the initiation and promotion of malignant disease Cancer Cell 2005 7 3 211 217 (Pubitemid 40568680)
99. Danese S., Malesci A., Vetrano S., Colitis-associated cancer: the dark side of inflammatory bowel disease Gut 2011 60 12 1609 1610
100. Shah Y. M., Morimura K., Gonzalez F. J., Expression of peroxisome proliferator-activated receptor- in macrophage suppresses experimentally induced colitis American Journal of Physiology 2007 292 2 G657 G666
101. Sarraf P., Mueller E., Smith W. M., Wright H. M., Jennifer B K., Aaltonen L. A., De Chapelle A. L., Spiegelman B. M., Charis E., Loss-of-function mutations in PPAR associated with human colon cancer Molecular Cell 1999 3 6 799 804 (Pubitemid 29323058)
102. Ikezoe T., Miller C. W., Kawano S., Heaney A., Williamson E. A., Hisatake J., Green E., Hofmann W., Taguchi H., Koeffler H. P., Mutational analysis of the peroxisome proliferator-activated receptor in human malignancies Cancer Research 2001 61 13 5307 5310 (Pubitemid 32681569)
103. Burgermeister E., Seger R., MAPK kinases as nucleo-cytoplasmic shuttles for PPAR Cell Cycle 2007 6 13 1539 1548 (Pubitemid 47327937)
104. Garcia-Bates T. M., Lehmann G. M., Simpson-Haidaris P. J., Bernstein S. H., Sime P. J., Phipps R. P., Role of peroxisome proliferator-activated receptor and its ligands in the treatment of hematological malignancies PPAR Research 2008 2008 18
105. Pancione M., Forte N., Sabatino L., Reduced beta-catenin and peroxisome proliferator-activated receptor- expression levels are associated with colorectal cancer metastatic progressione: correlation with tumor-associated macrophages, cyclooxygenase 2 and patient outcome Human Pathology 2009 40 5 714 725
106. Ogino S., Shima K., Baba Y., Nosho K., Irahara N., Kure S., Chen L., Toyoda S., Kirkner G. J., Wang Y. L., Giovannucci E. L., Fuchs C. S., Colorectal cancer expression of peroxisome proliferator-activated receptor (PPARG, PPAR ) is associated with good prognosis Gastroenterology 2009 136 4 1242 1250
107. Berdasco M., Esteller M., Aberrant epigenetic landscape in cancer: how cellular identity goes awry Developmental Cell 2010 19 5 698 711
108. Rakyan V. K., Down T. A., Balding D. J., Beck S., Epigenome-wide association studies for common human diseases Nature Reviews Genetics 2011 12 8 529 541
109. Vogelstein B., Fearon E. R., Hamilton S. R., Kern S. E., Preisinger A. C., Leppert M., Nakamura Y., White R., Smits A. M. M., Bos J. L., Genetic alterations during colorectal-tumor development New England Journal of Medicine 1988 319 9 525 532
110. Carmona F. J., Esteller M., Epigenomics of human colon cancer Mutation Research 2010 693 1-2 53 60
111. Esteller M., Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes European Journal of Cancer 2000 36 18 2294 2300
112. Feinberg A. P., Tycko B., The history of cancer epigenetics Nature Reviews Cancer 2004 4 2 143 153 (Pubitemid 38198742)
113. Venkatachalam R., Ligtenberg M. J., Hoogerbrugge N., de Bruijn D. R., Kuiper R. P., Geurts van Kessel A., The epigenetics of (hereditary) colorectal cancer Cancer Genetics and Cytogenetics 2010 203 1 1 6
114. Issa J. P., Colon cancer: it's CIN or CIMP Clinical Cancer Research 2008 14 19 5939 5940
115. Jin B., Yao B., Li J. L., Fields C. R., Delmas A. L., Liu C., Robertson K. D., DNMT1 and DNMT3B modulate distinct polycomb-mediated histone modifications in colon cancer Cancer Research 2009 69 18 7412 7421
116. Gowher H., Stockdale C. J., Goyal R., Ferreira H., Owen-Hughes T., Jeltsch A., De novo methylation of nucleosomal DNA by the mammalian Dnmt1 and Dnmt3A DNA methyltransferases Biochemistry 2005 44 29 9899 9904 (Pubitemid 41033456)
117. Nosho K., Shima K., Irahara N., Kure S., Baba Y., Kirkner G. J., Chen L., Gokhale S., Hazra A., Spiegelman D., Giovannucci E. L., Jaenisch R., Fuchs C. S., Ogino S., DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer Clinical Cancer Research 2009 15 11 3663 3671
118. Linhart H. G., Lin H., Yamada Y., Moran E., Steine E. J., Gokhale S., Lo G., Cantu E., Ehrich M., He T., Meissner A., Jaenisch R., Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing Genes and Development 2007 21 23 3110 3122 (Pubitemid 350223528)
119. Varier R. A., Timmers H. T. M., Histone lysine methylation and demethylation pathways in cancer Biochimica et Biophysica Acta 2011 1815 1 75 89
120. Lehnertz B., Ueda Y., Derijck A. A. H. A., Braunschweig U., Perez-Burgos L., Kubicek S., Chen T., Li E., Jenuwein T., Peters A. H. F. M., Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin Current Biology 2003 13 14 1192 1200 (Pubitemid 36872941)
121. Tachibana M., Ueda J., Fukuda M., Takeda N., Ohta T., Iwanari H., Sakihama T., Kodama T., Hamakubo T., Shinkai Y., Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9 Genes and Development 2005 19 7 815 826
122. zda H., Teschendorff A. E., Ahmed A. A., Hyland S. J., Blenkiron C., Bobrow L., Veerakumarasivam A., Burtt G., Subkhankulova T., Arends M. J., Collins V. P., Bowtell D., Kouzarides T., Brenton J. D., Caldas C., Differential expression of selected histone modifier genes in human solid cancers BMC Genomics 2006 7 90
123. Kondo Y., Shen L., Cheng A. S., Ahmed S., Boumber Y., Charo C., Yamochi T., Urano T., Furukawa K., Kwabi-Addo B., Gold D. L., Sekido Y., Huang T. H. M., Issa J. P. J., Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation Nature Genetics 2008 40 6 741 750 (Pubitemid 351748874)
124. Shilatifard A., Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation Current Opinion in Cell Biology 2008 20 3 341 348
125. Portela A., Esteller M., Epigenetic modifications and human disease Nature Biotechnology 2010 28 10 1057 1068
126. Vaissire T., Sawan C., Herceg Z., Epigenetic interplay between histone modifications and DNA methylation in gene silencing Mutation Research 2008 659 1-2 40 48
127. Meissner A., Mikkelsen T. S., Gu H., Wernig M., Hanna J., Sivachenko A., Zhang X., Bernstein B. E., Nusbaum C., Jaffe D. B., Gnirke A., Jaenisch R., Lander E. S., Genome-scale DNA methylation maps of pluripotent and differentiated cells Nature 2008 454 7205 766 770
128. Viré E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., Morey L., Van Eynde A., Bernard D., Vanderwinden J. M., Bollen M., Esteller M., Di Croce L., De Launoit Y., Fuks F., The Polycomb group protein EZH2 directly controls DNA methylation Nature 2006 439 7078 871 874 (Pubitemid 43255707)
129. Estve P. O., Hang G. C., Smallwood A., Feehery G. R., Gangisetty O., Karpf A. R., Carey M. F., Pradhan S., Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication Genes and Development 2006 20 22 3089 3103 (Pubitemid 44790625)
130. Epsztejn-Litman S., Feldman N., Abu-Remaileh M., Shufaro Y., Gerson A., Ueda J., Deplus R., Fuks F., Shinkai Y., Cedar H., Bergman Y., De novo DNA methylation promoted by G9a prevents reprogramming of embryonically silenced genes Nature Structural and Molecular Biology 2008 15 11 1176 1183
131. Parry L., Clarke A. R., The roles of the methyl-CpG binding proteins in cancer Genes and Cancer 2011 2 6 618 630
132. Nan X., Ng H. H., Johnson C. A., Laherty C. D., Turner B. M., Eisenman R. N., Bird A., Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex Nature 1998 393 6683 386 389 (Pubitemid 28269714)
133. Rottach A., Frauer C., Pichler G., Bonapace I. M., Spada F., Leonhardt H., The multi-domain protein Np95 connects DNA methylation and histone modification Nucleic Acids Research 2009 38 6 1796 1804
134. Tien A. L., Senbanerjee S., Kulkarni A., Mudbhary R., Goudreau B., Ganesan S., Sadler K. C., Ukomadu C., UHRF1 depletion causes a G2/M arrest, activation of DNA damage response and apoptosis Biochemical Journal 2011 435 1 175 185
135. Meilinger D., Fellinger K., Bultmann S., Rothbauer U., Bonapace I. M.,
136. Kogo R., Shimamura T., Mimori K., Long non-coding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers Cancer Research 2011 71 20 6320 6326
137. Gibb E. A., Brown C. J., Lam W. L., The functional role of long non-coding RNA in human carcinomas Molecular Cancer 2011 10 38
138. Fujiki K., Kano F., Shiota K., Murata M., Expression of the peroxisome proliferator activated receptor gene is repressed by DNA methylation in visceral adipose tissue of mouse models of diabetes BMC Biology 2009 7 38
139. Salma N., Xiao H., Mueller E., Imbalzano A. N., Temporal recruitment of transcription factors and SWI/SNF chromatin-remodeling enzymes during adipogenic induction of the peroxisome proliferator-activated receptor nuclear hormone receptor Molecular and Cellular Biology 2004 24 11 4651 4663 (Pubitemid 38668033)
140. Mann J., Oakley F., Akiboye F., Elsharkawy A., Thorne A. W., Mann D. A., Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis Cell Death and Differentiation 2007 14 2 275 285 (Pubitemid 46092230)
141. Pancione M., Sabatino L., Fucci A., Carafa V., Nebbioso A., Forte N., Febbraro A., Parente D., Ambrosino C., Normanno N., Altucci L., Colantuoni V., Epigenetic silencing of peroxisome proliferator- activated receptor is a biomarker for colorectal cancer progression and adverse patients' outcome PLoS ONE 2010 5 12
142. Sabatino L., Fucci A., Pancione M., Carafa V., Nebbioso A., Pistore C., Babbio F., Votino C., Laudanna C., Ceccarelli M., Altucci L., Bonapace I. M., Colantuoni V., UHRF1 coordinates peroxisome proliferator activated receptor (PPARG) epigenetic silencing and mediates colorectal cancer progression. Oncogene. In press
143. Rogers H. A., Kilday J. P., Mayne C., Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death Acta Neuropathologica 2012 123 5 711 725